Drug Profile
Research programme: XTEN and ProTIA based therapeutics - Amunix/Celgene
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Amunix; Celgene Corporation
- Class Antineoplastics; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in USA
- 17 Jan 2022 Amunix has been acquired by Sanofi
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb